Notice on Convening the 2025 Annual General Meeting
Filed with SSE · · 10 pages · Chinese
Earlier from RemeGen
- Announcement on Resolutions of the 38th Meeting of the 2nd Board of Directors
- Announcement on Participation in the "Dialogue on Growth" 2025 and Q1 2026 Collective Performance Briefing
- Report for Q1 2026
- Science and Technology for People's Well-being - Achievement of Enterprises on SSE STAR Market and Its Empowerment of People's Livelihood Conference
- Announcement on Voluntary Disclosure of Approval of Marketing Application for Vedicizumab as the First-line Treatment for HER2-Low Expressing Urothelial Carcinoma
Later from RemeGen
- Announcement on Voluntary Disclosure of the Conditional Marketing Application for Telitacicept for the Treatment of IgA Nephropathy
- Announcement on Election of Employee Representative Directors for the 3rd Board of Directors
- Announcement on Circulation of Restricted Shares in Initial Public Offering
- Announcement on Resolutions of the 2nd Meeting of the 3rd Board of Directors
- Announcement on Shareholdings of Top 10 Shareholders and Top 10 Shareholders of Unrestricted Shares Concerning First Share Repurchase in 2026
Follow RemeGen into a list and get an email when it puts out news.
Follow RemeGen